Thursday, January 17, 2019

Comparison of State-by-State Data Shows Melanoma Survival Varies Regionally

Cancer of the skin is by far the most common of all cancers and while melanoma accounts for only about 1% of all skin cancers, it causes a large majority of skin cancer deaths. According to data from the American Cancer Society, melanoma is more than 20 times more common in whites than in African Americans. Furthermore, the overall, lifetime,...

Study Confirms Complication Rates and Costs for Drugs and Diagnostics Higher in Lung Cancer

According to a new study from The University of Texas MD Anderson Cancer Center, complication rates following invasive diagnostic procedures for lung abnormalities were twice as high in the community setting compared to those reported in lung cancer screening trials. The procedures were also associated downstream average costs ranging from U.S. $ 6,320 to U.S. $ 56,845. In the study,...

Tailoring Treatment to Men or Women with Glioblastoma May Improve Survival

A new study by researchers at the Washington University School of Medicine in St. Louis suggest that tailoring treatments to men and women with glioblastoma, based on the molecular subtypes of their tumors, may help improve survival. The study, supported by National Institutes of Health (NIH),  the Children’s Discovery Institute of Washington University, Joshua’s Great Things, the James S. McDonnell...

A Compound Being Developed to Treat an Eye Disease may also Kill Leukemia Cells

An active ingredient in eye drops called SPHINX31, being developed for the treatment of a form of eye disease, has shown promise for treating an aggressive form of blood cancer called Acute Myeloid Leukemia or AML. Scientists at the Wellcome Sanger Institute, University of Cambridge, University of Nottingham and their collaborators have found that this compound, which targets an essential...

Medical Imaging Modalities for Prostate Cancer Diagnosis

Prostate cancer, which usually occurs in older men, is the second prevent type of cancer that exists. Approximately 11.2% of men will be diagnosed with prostate cancer at some point during their lifetime. Although it is usually a slowly progressing disease, prostate cancer can sometimes manifest as an aggressive cancer. The primary way to diagnose the disease is via prostate...

Drug Cocktail Inhibits Tumor Growth

Syrosingopine (O-carbethoxysyringoyl methylreserpate; SU-3118), a drug derived from reserpine* which was originally developed by Ciba (now Novartis) for the treatment of hypertension in 1958, in combination with the widely used diabetes drug metformin, an oral antidiabetic of the biguanide class, killed tumor cells in blood samples from leukemia patients, while it did not damage blood cells in samples from...

Specific Class of Biomarkers May help Take Uncertainty Out of Cancer Prognosis

A cancer diagnosis is a terrifying experience, and for most patients the associated uncertainty is especially frightening. Researchers at Cold Spring Harbor Laboratory in Cold Spring Harbor, New York, have now identified a specific class of biomarkers that may help them predict how how aggressive a patient's cancer will be. "There are undoubtedly dozens or hundreds of mutations that cause...

Focused Ultrasound-assisted Treatment helps drugs Cross Blood Brain Barrier

Study results of a research team led by scientists at the Massachusetts General Hospital (MGH), Boston, Massachusetts, shows, for the first time, the mechanisms underlying the use of Focused Ultrasound (FUS) to improve the delivery of anti-cancer drugs across the blood brain barrier into brain tumors. The blood–brain/blood–tumor barriers (BBB and BTB) and interstitial transport constitute major obstacles to the...

Phase III ARCHES Trial Shows Positive Results for Enzalutamide in Prostate Cancer

Despite improved treatment options for patients progressing on standard hormone treatment, metastatic prostate cancer still remains a deadly disease. For men with metastatic hormone-sensitive prostate cancer (mHSPC), starting standard androgen deprivation therapy (ADT), the median overall survival (OS) is approximately 45 months. However, for patients with higher-volume disease, the median survival was less (35.1 and 32.2 months, respectively). ADT has long...

Childhood Lymphoma Survivors have Elevated Risk of Solid Cancers

With new and advanced treatments, most children treated for various forms of lymphoma have the opportunity to survive into adulthood.  These patients are, however, at risk, for several possible late adverse effects of their cancer treatment. This risk depends on a number of factors, such as the type of lymphoma, the type and doses of treatments, and the child's age...

Related articles